vs

Side-by-side financial comparison of DIGI INTERNATIONAL INC (DGII) and Health Catalyst, Inc. (HCAT). Click either name above to swap in a different company.

DIGI INTERNATIONAL INC is the larger business by last-quarter revenue ($122.5M vs $74.7M, roughly 1.6× Health Catalyst, Inc.). DIGI INTERNATIONAL INC runs the higher net margin — 9.6% vs -121.9%, a 131.5% gap on every dollar of revenue. On growth, DIGI INTERNATIONAL INC posted the faster year-over-year revenue change (17.9% vs -6.2%). DIGI INTERNATIONAL INC produced more free cash flow last quarter ($35.2M vs $9.6M). Over the past eight quarters, DIGI INTERNATIONAL INC's revenue compounded faster (6.6% CAGR vs -0.0%).

Digi International, Inc. is an American Industrial Internet of Things (IIoT) technology company based in Hopkins, Minnesota. Founded in 1985, they were best known in the early 1990s as a manufacturer of multi-line serial data serial cards for PC clones, allowing these machines to run multi-line bulletin board systems (BBSes). As this market began to wind down with the rise of the internet in the late 1990s, Digi began to concentrate on network attached devices and industrial monitoring.

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Fir...

DGII vs HCAT — Head-to-Head

Bigger by revenue
DGII
DGII
1.6× larger
DGII
$122.5M
$74.7M
HCAT
Growing faster (revenue YoY)
DGII
DGII
+24.1% gap
DGII
17.9%
-6.2%
HCAT
Higher net margin
DGII
DGII
131.5% more per $
DGII
9.6%
-121.9%
HCAT
More free cash flow
DGII
DGII
$25.5M more FCF
DGII
$35.2M
$9.6M
HCAT
Faster 2-yr revenue CAGR
DGII
DGII
Annualised
DGII
6.6%
-0.0%
HCAT

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
DGII
DGII
HCAT
HCAT
Revenue
$122.5M
$74.7M
Net Profit
$11.7M
$-91.0M
Gross Margin
62.4%
Operating Margin
13.3%
-115.3%
Net Margin
9.6%
-121.9%
Revenue YoY
17.9%
-6.2%
Net Profit YoY
16.1%
-340.3%
EPS (diluted)
$0.31
$-1.29

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DGII
DGII
HCAT
HCAT
Q4 25
$122.5M
$74.7M
Q3 25
$114.3M
$76.3M
Q2 25
$107.5M
$80.7M
Q1 25
$104.5M
$79.4M
Q4 24
$103.9M
$79.6M
Q3 24
$105.1M
$76.4M
Q2 24
$105.2M
$75.9M
Q1 24
$107.7M
$74.7M
Net Profit
DGII
DGII
HCAT
HCAT
Q4 25
$11.7M
$-91.0M
Q3 25
$10.0M
$-22.2M
Q2 25
$10.2M
$-41.0M
Q1 25
$10.5M
$-23.7M
Q4 24
$10.1M
$-20.7M
Q3 24
$11.9M
$-14.7M
Q2 24
$9.7M
$-13.5M
Q1 24
$4.0M
$-20.6M
Gross Margin
DGII
DGII
HCAT
HCAT
Q4 25
62.4%
Q3 25
63.9%
52.6%
Q2 25
63.5%
Q1 25
62.1%
Q4 24
62.0%
Q3 24
61.1%
47.5%
Q2 24
59.2%
Q1 24
57.9%
Operating Margin
DGII
DGII
HCAT
HCAT
Q4 25
13.3%
-115.3%
Q3 25
12.5%
-22.9%
Q2 25
13.9%
-46.0%
Q1 25
13.1%
-25.4%
Q4 24
12.9%
-22.0%
Q3 24
14.2%
-17.9%
Q2 24
12.3%
-20.8%
Q1 24
7.6%
-30.5%
Net Margin
DGII
DGII
HCAT
HCAT
Q4 25
9.6%
-121.9%
Q3 25
8.7%
-29.1%
Q2 25
9.5%
-50.8%
Q1 25
10.0%
-29.9%
Q4 24
9.7%
-26.0%
Q3 24
11.3%
-19.3%
Q2 24
9.2%
-17.8%
Q1 24
3.7%
-27.6%
EPS (diluted)
DGII
DGII
HCAT
HCAT
Q4 25
$0.31
$-1.29
Q3 25
$0.26
$-0.32
Q2 25
$0.27
$-0.59
Q1 25
$0.28
$-0.35
Q4 24
$0.27
$-0.33
Q3 24
$0.32
$-0.24
Q2 24
$0.26
$-0.23
Q1 24
$0.11
$-0.35

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DGII
DGII
HCAT
HCAT
Cash + ST InvestmentsLiquidity on hand
$30.9M
$95.7M
Total DebtLower is stronger
$135.0M
$153.3M
Stockholders' EquityBook value
$649.2M
$245.8M
Total Assets
$918.4M
$502.6M
Debt / EquityLower = less leverage
0.21×
0.62×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DGII
DGII
HCAT
HCAT
Q4 25
$30.9M
$95.7M
Q3 25
$21.9M
$91.5M
Q2 25
$20.1M
$97.3M
Q1 25
$26.3M
$342.0M
Q4 24
$25.9M
$392.0M
Q3 24
$27.5M
$387.3M
Q2 24
$28.3M
$308.3M
Q1 24
$23.8M
$327.8M
Total Debt
DGII
DGII
HCAT
HCAT
Q4 25
$135.0M
$153.3M
Q3 25
$159.2M
$153.1M
Q2 25
$40.1M
$153.0M
Q1 25
$70.0M
$382.9M
Q4 24
$95.0M
$382.4M
Q3 24
$123.2M
$345.0M
Q2 24
$151.6M
Q1 24
$171.8M
Stockholders' Equity
DGII
DGII
HCAT
HCAT
Q4 25
$649.2M
$245.8M
Q3 25
$636.1M
$331.9M
Q2 25
$621.5M
$347.5M
Q1 25
$605.2M
$376.8M
Q4 24
$590.7M
$365.2M
Q3 24
$581.0M
$355.0M
Q2 24
$563.1M
$357.0M
Q1 24
$549.6M
$357.2M
Total Assets
DGII
DGII
HCAT
HCAT
Q4 25
$918.4M
$502.6M
Q3 25
$922.6M
$587.1M
Q2 25
$770.3M
$616.2M
Q1 25
$781.0M
$891.5M
Q4 24
$796.1M
$858.9M
Q3 24
$815.1M
$813.0M
Q2 24
$820.4M
$691.7M
Q1 24
$825.3M
$695.1M
Debt / Equity
DGII
DGII
HCAT
HCAT
Q4 25
0.21×
0.62×
Q3 25
0.25×
0.46×
Q2 25
0.06×
0.44×
Q1 25
0.12×
1.02×
Q4 24
0.16×
1.05×
Q3 24
0.21×
0.97×
Q2 24
0.27×
Q1 24
0.31×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DGII
DGII
HCAT
HCAT
Operating Cash FlowLast quarter
$35.6M
$9.9M
Free Cash FlowOCF − Capex
$35.2M
$9.6M
FCF MarginFCF / Revenue
28.7%
12.9%
Capex IntensityCapex / Revenue
0.4%
0.4%
Cash ConversionOCF / Net Profit
3.04×
TTM Free Cash FlowTrailing 4 quarters
$111.4M
$-697.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DGII
DGII
HCAT
HCAT
Q4 25
$35.6M
$9.9M
Q3 25
$28.0M
$-464.0K
Q2 25
$24.0M
$-9.0M
Q1 25
$26.3M
$280.0K
Q4 24
$29.7M
$-3.5M
Q3 24
$26.4M
$6.2M
Q2 24
$24.9M
$1.6M
Q1 24
$13.1M
$10.3M
Free Cash Flow
DGII
DGII
HCAT
HCAT
Q4 25
$35.2M
$9.6M
Q3 25
$27.5M
$-719.0K
Q2 25
$22.9M
$-9.2M
Q1 25
$25.7M
$-390.0K
Q4 24
$29.1M
$-3.9M
Q3 24
$25.5M
$5.5M
Q2 24
$24.5M
$1.3M
Q1 24
$12.5M
$10.1M
FCF Margin
DGII
DGII
HCAT
HCAT
Q4 25
28.7%
12.9%
Q3 25
24.1%
-0.9%
Q2 25
21.3%
-11.4%
Q1 25
24.6%
-0.5%
Q4 24
28.1%
-4.9%
Q3 24
24.3%
7.2%
Q2 24
23.2%
1.7%
Q1 24
11.6%
13.5%
Capex Intensity
DGII
DGII
HCAT
HCAT
Q4 25
0.4%
0.4%
Q3 25
0.4%
0.3%
Q2 25
0.9%
0.3%
Q1 25
0.5%
0.8%
Q4 24
0.6%
0.5%
Q3 24
0.9%
0.9%
Q2 24
0.5%
0.4%
Q1 24
0.5%
0.3%
Cash Conversion
DGII
DGII
HCAT
HCAT
Q4 25
3.04×
Q3 25
2.81×
Q2 25
2.34×
Q1 25
2.50×
Q4 24
2.95×
Q3 24
2.23×
Q2 24
2.57×
Q1 24
3.27×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DGII
DGII

Io T Productsand Services$86.4M71%
Io T Solutions$36.1M29%

HCAT
HCAT

Recurring Technology$51.9M69%
Professional Services$22.8M31%

Related Comparisons